MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2016 International Congress

    The role of non-steroidal anti-inflammatory use in symptomatic and asymptomatic LRRK2 G2019S mutation carriers

    K.A. Wyman-Chick, M.J. Barrett, S.A. Sperling, C.A. Manning (Charlottesville, VA, USA)

    Objective: The purpose of the current study is to determine if non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of Parkinson's disease (PD) among LRRK2 G2019S…
  • 2016 International Congress

    High throughput pooled-DNA sequencing of mendelian/susceptibility Parkinson’s disease genes in Spanish population

    S. Ortega-Cubero, O. Lorenzo-Betancor, E. Lorenzo, B.A. Benitez, C. Cruchaga, L. Samaranch, M. Diez, J.A. Obeso, M.C. Rodriguez-Oroz, M. Aguilar, M.A. Pastor, P. Pastor (Palencia, Spain)

    Objective: The primary outcome of our study was the identification of rare variants in 5 major Mendelian PD genes (SNCA, PARK2, PINK1, DJ1, LRRK2) and…
  • 2016 International Congress

    A novel haplotype in LRRK2 is associated with risk for multiple system atrophy in the Korean population

    L.L. Farrell, E. Scott, H.J. Kim, I. Guella, S. Bortnick, E.M. Nosova, B. Jeon, C.W. Sin, H. Park, S.S. Park, M.J. Farrer (Vancouver, Cameroon)

    Objective: To (1) validate past results by investigating the role of LRRK2 exonic variants in an equivalent Korean series with MSA and (2) identify novel…
  • 2016 International Congress

    Defective ubiquitinated mitochondria accumulation in aged Parkinsonian LRRK2R1441G knockin mice

    H.F. Liu, P.W.L. Ho, L.F. Li, G.C.T. Leung, C.S.C. Lam, M.H.W. Kung, D.B. Ramsden, S.L. Ho (Hong Kong, Hong Kong)

    Objective: (1) To determine potential accumulation of defective ubiquitinated mitochondria in the brains of aged LRRK2R1441G knockin (KI) mice and their age-matched wildtype controls; and…
  • 2016 International Congress

    Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease

    J. Varghese, K. Terpstra, S. Chiu, R. Mishra, Y. Bureau (London, ON, Canada)

    Objective: The objective of our study was to characterize the behavioral phenotype of the transgenic LRRK-2 rat in the context of PD model and to…
  • 2016 International Congress

    Detection of leucine-rich repeat kinase 2 in human biofluids

    E. Mutez, W. Sibran, T. Comptdaer, P. Semaille, M. Drouyer, S. Bleuse, L. Defebvre, A. Destee, M.C. Chartier-Harlin, J.M. Taymans (Lille, France)

    Objective: To evaluate the presence of leucine-rich repeat kinase 2 (LRRK2) in human biosamples, including cerebrospinal fluid (CSF) and urine, as a first step towards…
  • 2016 International Congress

    A cognitive fMRI study of non-manifesting LRRK2 and GBA carriers

    A. Thaler, N. Bregman, A. Mirelman, T. Gurevich, M. Gana-Weiss, A. Orr-Urtreger, T. Hendler, N. Giladi (Tel-Aviv, Israel)

    Objective: To assess the cognitive profile of non-manifesting carriers of GBA and LRRK2 mutations using two fMRI tasks: a Stroop interference and N-Back working memory…
  • 2016 International Congress

    Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity

    C.H. Lin, H.I. Lin, M.L. Chen, T.T. Lai, L.P. Cao, M.J. Farrer, R.M. Wu, C.T. Chien (Taipei, Taiwan)

    Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley